The FDA on November 16, 2018 approved ADCETRIS® in combination with chemotherapy for previously untreated systemic Anaplastic Large Cell Lymphoma or other CD30-expressing Peripheral T-Cell Lymphomas. ADCETRIS® is a product of Seattle Genetics Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
